{
    "clinical_study": {
        "@rank": "45086", 
        "arm_group": {
            "arm_group_label": "Recombinant human acid sphingomyelinase", 
            "arm_group_type": "Experimental", 
            "description": "Participants will receive rhASM of an initial dose of 0.1 mg/kg, followed by several dose escalations, as tolerated, up to 3.0 mg/kg. All doses are given 2 weeks apart."
        }, 
        "brief_summary": {
            "textblock": "To evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic profile of rhASM\n      in adult patients with Acid Sphingomyelinase Deficiency (ASMD) following repeated-dose\n      administration."
        }, 
        "brief_title": "Tolerability and Safety Study of Recombinant Human Acid Sphingomyelinase in Acid Sphingomyelinase Deficiency Patients", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Human Acid Sphingomyelinase Deficiency", 
        "condition_browse": {
            "mesh_term": [
                "Niemann-Pick Diseases", 
                "Niemann-Pick Disease, Type A", 
                "Niemann-Pick Disease, Type C"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with documented non-neuronopathic acid sphingomyelinase deficiency\n\n          -  The patient has a diffusing capacity of carbon monoxide (DLco) >20% and \u226480% of the\n             predicted normal value.\n\n          -  The patient has a spleen volume \u22656 multiples of normal(MN). A partial splenectomy\n             will be permitted if performed \u22651 year prior to Screening/Baseline and residual\n             spleen volume is \u22656 MN.\n\n          -  The patient who is receiving lipid lowering therapy should be on a stable dose and\n             regimen of lipid-lowering therapy(ies) for at least 12 weeks prior to\n             Screening/Baseline, with the patient expected to remain on the same dose and regimen\n             throughout the 26-week treatment period.\n\n          -  The patient who is female and of childbearing potential must have a negative serum\n             pregnancy test for \u03b2-HCG.\n\n        Exclusion Criteria:\n\n          -  The patient is female and pregnant or lactating.\n\n          -  The patient has a Body Mass Index(BMI)>30.\n\n          -  The patient has received an investigational drug within 30 days prior to study\n             enrollment\n\n          -  The patient has a medical condition or any extenuating circumstance that may\n             significantly interfere with study compliance, including all prescribed evaluations\n             and follow-up activities.\n\n          -  The patient has had a major organ transplant\n\n          -  ALT or AST >250 IU/L or total bilirubin >1.5 mg/dL.\n\n          -  The patient is unwilling or unable to abstain from the use of alcohol for 1 day prior\n             to and 3 days after each rhASM infusion for the duration of the study.\n\n          -  The patient requires medications that may decrease rhASM\n\n          -  The patient is unwilling or unable to avoid the use of medications or herbal\n             supplements that may cause or prolong bleeding, or have potential hepatotoxicity\n             within 10 days prior to and 3 days after liver biopsy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "5", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 5, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01722526", 
            "org_study_id": "DFI13412", 
            "secondary_id": "2012-003542-32"
        }, 
        "intervention": {
            "arm_group_label": "Recombinant human acid sphingomyelinase", 
            "description": "Administered intravenously every 2 weeks for 26 weeks", 
            "intervention_name": "Recombinant human acid sphingomyelinase", 
            "intervention_type": "Drug", 
            "other_name": "GZ402665"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Human acid sphingomyelinase deficiency", 
        "lastchanged_date": "January 16, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }, 
                    "name": "Mount Sinai School of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom"
                    }, 
                    "name": "St. Mary's Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-label, Multicenter, Ascending Dose Study of the Tolerability and Safety of Recombinant Human Acid Sphingomyelinase (rhASM) in Patients With Acid Sphingomyelinase Deficiency (ASMD)", 
        "overall_official": {
            "affiliation": "Genzyme, a Sanofi Company", 
            "last_name": "Medical Monitor", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Summary of Adverse Events (AEs)", 
            "safety_issue": "Yes", 
            "time_frame": "at least 26 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01722526"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics as measured by peak plasma concentration (Cmax), time to peak concentration (tmax), area under curve (AUC), half life (t1/2), drug clearance (CL), and volume of distribution (Vss)", 
                "safety_issue": "No", 
                "time_frame": "up to 26 weeks"
            }, 
            {
                "measure": "Pharmacodynamics as measured by liver and skin biopsies, plasma, and  dried blood spot", 
                "safety_issue": "No", 
                "time_frame": "up to 26 weeks"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genzyme, a Sanofi Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}